Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise questions about how much of the recent progress is already reflected in the share price.
-
Over the last three years, ImmunityBio has returned 321.9%, which puts recent short term pullbacks into the context of a very strong multi year run.
-
Approval for ANKTIVA in the UAE and growing commercial traction can support higher revenue expectations, while execution risk around wider regulatory approvals and treatment uptake may still influence how investors price the stock.
-
On Simply Wall St's checks, ImmunityBio screens as mixed value, with 3 of 6 valuation measures suggesting the stock is on the expensive side rather than a clear bargain.
The issue now is whether the recent share price around US$7.32 still leaves enough upside potential to justify ImmunityBio's current valuation.
Is ImmunityBio Getting Expensive on Sales?
P/S can be a useful guide for ImmunityBio because the company is still building toward profitability and investors often focus on how much they are paying for each dollar of sales.
On this measure, ImmunityBio trades on a P/S of about 46.8x, compared with an industry average of roughly 11.6x and a peer group average near 13.6x for biotechs. The fair P/S ratio implied by Simply Wall St's model is about 37.1x, which reflects what investors might expect to pay given ImmunityBio's business profile and risk level.
Despite the recent approval of ANKTIVA in the UAE and the reported net product revenue in 2026, the current multiple still sits well above that fair ratio benchmark. The gap suggests investors are already paying a significant premium for ImmunityBio relative to both its industry and the modelled fair level.
On the P/S multiple, ImmunityBio stock currently appears expensive compared with both tailored and industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The ImmunityBio Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for ImmunityBio pick up where this valuation puzzle leaves off and spell out what growth, margins and earnings path would need to play out for the stock to be worth materially more or less than today's price, and they sit on the company's Community page. Rather than a single multiple or model output, each one lays out the key assumptions behind its fair value so you can compare those with ImmunityBio's reported results over time.
One of the top community narratives on ImmunityBio: 44% undervalued
"The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth…"
Read one of the top narratives on ImmunityBio
Do you think there's more to the story for ImmunityBio? Head over to our Community to see what others are saying!
The Bottom Line
For ImmunityBio, the market multiple view points to an overvalued stock where investors are already paying up for potential. The value checks are mixed rather than clearly supportive, which keeps the burden of proof on the company to show that commercial execution can catch up with expectations. After such an extreme share price move, the key question is whether future progress on ANKTIVA approvals and uptake justifies holding a premium P/S or whether sentiment cools and the multiple settles closer to peers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IBRX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
